Cg Oncology Inc (CGON) Stock Price, Quote & News

Company Profile

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of pa...

Industry: Biotechnology

Sector: Healthcare

Phone: 949 409 3700

Website: cgoncology.com

Address:

400 Spectrum Center Drive, Suite 2040, Irvine, United States

Buy_SoFi Apr. 24 at 7:52 PM

$1.00+ by EoY Ferring already partnered with $TLTFF and I can only assume the new cohort of test patients are in the process of being treated for NMIBC. More partners will probably knock on the door; MIBC, GBM/Brain, Lung, pancreatic and HSV topical treatment. This has a multi-dollar buyout written all over... $IBRX $GSK $CGON $JNJ

0 · Reply

PlutoAnalyses Apr. 24 at 3:19 PM

$CGON this is the full analysis: If you want to know what the valuation of a clinical stage bladder cancer focused company might loon like check out my article on Substack: There are many benefits, of CGON’s drug Creto, but also some potential caveats for example the DoR. The article is free. https://open.substack.com/pub/plutoanalyses/p/cg-oncology-the-institutional-crown?r=5e6tza&utm_medium=ios

0 · Reply

PlutoAnalyses Apr. 24 at 2:49 PM

$CGON VALUATION OUT NOW 1. Safety & efficacy are superior to $IBRX's Anktiva in bladder cancer. 2. 700M in cash, providing runway to complete trials and negotiating leverage 3. great buyout target PLUTO VALUE: 2.13x Read the full article for free here: https://open.substack.com/pub/plutoanalyses/p/cg-oncology-the-institutional-crown?utm_campaign=post-expanded-share&utm_medium=web $IBB $XBI

2 · Reply

IronManResurrection Apr. 24 at 1:46 PM

$CGON $IBRX how does one not understand Anktiva is complimentary with almost every treatment vector? It could be relegated to a supporting role across the entire spectrum of illness and infection. It’s either making the treatment plan more efficacious or rescuing the SoC. It’s a win-win, only a juvenile untrained mind goes head-to-head with rigid exclusionary thinking.

1 · Reply

PlutoAnalyses Apr. 24 at 1:16 PM

Got this one guy @BenUnknown feelings hurt. He thinks $IBRX is not going to compete in NMIBC against $CGON because of the MoA. Cytokine is just part of Creto’s mechanism. The bottom line it that its better than Anktiva in bot safety and tolerability but not in PFS.

2 · Reply

OmarKingW Apr. 24 at 12:52 PM

$CGON $IBRX MUTE/BLOCK

1 · Reply

PlutoAnalyses Apr. 24 at 12:46 PM

$CGON analysis coming at 10:30 today. Could Creto beat $IBRX’s Anktiva?

1 · Reply

Buy_SoFi Apr. 24 at 6:20 AM

$CGON $IBRX Nah... $TLTFF Has a much better and more promising pipeline than $CGON. I STRONGLY suggest doing DD on theralase, once in a lifetime opportunity at rock bottom price. Generational wealth making opportunity.

0 · Reply

PlutoAnalyses Apr. 23 at 11:09 PM

Gonna post a $CGON analysis tomorrow. 111% of CGON shares are held by institutions. This makes the stock super interesting to me. It seems like many institutions are longing the stock, while others are shorting it.

0 · Reply

PlutoAnalyses Apr. 23 at 11:00 PM

What are people thinking about $CGON over $IBRX?

3 · Reply

CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates

Feb 23, 2026, 8:00 AM EST - 2 months ago

CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference

Jan 9, 2026, 8:30 AM EST - 3 months ago

CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC

Jan 6, 2026, 8:00 AM EST - 3 months ago

CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 5, 2025, 8:30 AM EST - 5 months ago

New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer

Nov 26, 2025, 7:00 AM EST - 5 months ago

CG Oncology Announces New Board Member and Board Transition

Nov 14, 2025, 8:00 AM EST - 5 months ago

CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates

Sep 8, 2025, 9:08 AM EDT - 8 months ago

CG Oncology Stock Signals Bullish Momentum Ahead

Sep 5, 2025, 7:00 AM EDT - 8 months ago

CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months

Sep 3, 2025, 8:00 AM EDT - 8 months ago

CG Oncology Completes Enrollment in PIVOT-006

Aug 8, 2025, 8:00 AM EDT - 9 months ago

CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jun 5, 2025, 8:00 AM EDT - 11 months ago

CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 13, 2025, 8:00 AM EDT - 1 year ago

CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

Apr 28, 2025, 11:14 AM EDT - 1 year ago

CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why

Apr 26, 2025, 4:10 PM EDT - 1 year ago

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

Feb 26, 2025, 8:00 AM EST - 1 year ago

CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference

Dec 16, 2024, 4:05 PM EST - 1 year ago

CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Dec 12, 2024, 8:19 PM EST - 1 year ago

CG Oncology Announces Pricing of Public Offering

Dec 11, 2024, 6:17 AM EST - 1 year ago

CG Oncology Announces Proposed Public Offering

Dec 6, 2024, 1:18 PM EST - 1 year ago

Health Rounds: Experimental CG Oncology immunotherapy shows promise in bladder cancer

Dec 6, 2024, 8:00 AM EST - 1 year ago

SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

Dec 5, 2024, 7:00 AM EST - 1 year ago

Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Aug 30, 2024, 8:00 AM EDT - 1 year ago

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 8, 2024, 8:23 AM EDT - 1 year ago

CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates

Jun 6, 2024, 12:14 PM EDT - 2 years ago

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC

May 24, 2024, 8:00 AM EDT - 2 years ago

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

May 9, 2024, 8:00 AM EDT - 2 years ago

CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates

May 3, 2024, 11:23 AM EDT - 2 years ago

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Apr 26, 2024, 8:00 AM EDT - 2 years ago

CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024

Apr 24, 2024, 10:00 AM EDT - 2 years ago

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

Mar 28, 2024, 8:00 AM EDT - 2 years ago

CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting

Jan 30, 2024, 7:00 AM EST - 2 years ago

CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 29, 2024, 8:14 AM EST - 2 years ago

American Healthcare REIT, Fortegra and Fractyle Health set IPO price ranges as thaw continues

BTSG

Jan 26, 2024, 11:50 AM EST - 2 years ago

Biotech's First IPO of 2024 Popped 96%. What It Means.

Jan 25, 2024, 1:46 PM EST - 2 years ago

CG Oncology valued at $1.75 bln in strong market debut

Jan 25, 2024, 7:51 AM EST - 2 years ago

CG Oncology IPO prices above range and boosts share count in bullish move ahead of trading

Jan 24, 2024, 7:10 PM EST - 2 years ago

CG Oncology Announces Pricing of Upsized Initial Public Offering

Buy_SoFi Apr. 24 at 7:52 PM

0 · Reply

PlutoAnalyses Apr. 24 at 3:19 PM

0 · Reply

PlutoAnalyses Apr. 24 at 2:49 PM

2 · Reply

IronManResurrection Apr. 24 at 1:46 PM

1 · Reply

PlutoAnalyses Apr. 24 at 1:16 PM

2 · Reply

OmarKingW Apr. 24 at 12:52 PM

$CGON $IBRX MUTE/BLOCK

1 · Reply

PlutoAnalyses Apr. 24 at 12:46 PM

$CGON analysis coming at 10:30 today. Could Creto beat $IBRX’s Anktiva?

1 · Reply

Buy_SoFi Apr. 24 at 6:20 AM

0 · Reply

PlutoAnalyses Apr. 23 at 11:09 PM

0 · Reply

PlutoAnalyses Apr. 23 at 11:00 PM

What are people thinking about $CGON over $IBRX?

3 · Reply

Buy_SoFi Apr. 23 at 6:01 PM

$TLTFF <---- Multi-multi bagger in the making. Mark this post. $CGON $MRK $IBRX $GSK

0 · Reply

Buy_SoFi Apr. 23 at 4:14 PM

$TLTFF Keeps moving up... Still cheap! Don't miss out... - HSV Topical (better than anything on market) - NMIBC - MIBC - Brain/GBM - Lung - Ruvidar + Rutherin - Ferring Partnership $MRK $CGON $IBRX $GSK

0 · Reply

Buy_SoFi Apr. 21 at 2:36 PM

$TLTFF 100% CR and survival for X-Ray activated Rutherin for MIBC. WOW! Topical Ruvidar showing better results for HSV than anything available on the market. $MRK $IBRX $CGON $GSK

0 · Reply

Doozio Apr. 19 at 3:40 PM

$CGON Thursday 🐑 🎁 ONTO…..

0 · Reply

BioPM1989 Apr. 18 at 10:21 PM

$TYRA Don't think the erda PK translates here... Prefer deep value for NMIBC like $CGON

0 · Reply

Grinding10 Apr. 17 at 9:34 PM

$CGON 🤷‍♂️anyone want this 👊take my 30 years of trading bios or don’t I don’t really give a fuck anymore 😃KNEL 🫵✌️still here but goals getting achieved and trimming accordingly 🤷‍♂️still monster in IRA; done posting 👍

1 · Reply

JuggernautRaider Apr. 17 at 7:58 PM

$CGON hell of a run 🏃‍♂️

0 · Reply

anachartanalyst Apr. 17 at 5:02 PM

$CGON https://anachart.com/wp-content/uploads/ana_temp/1776445301_soc-img.jpg

0 · Reply

Quantumup Apr. 17 at 12:24 PM

Cantor reiterated $TYRA at an Overweight rating $URGN $CGON JNJ IBRX Here's what Cantor said in its note: https://x.com/Quantumup1/status/2045115106401431856?s=20

0 · Reply

Grinding10 Apr. 16 at 2:55 PM

$CGON jump on this anyone who knows; Easy manipulated tanking before approval or results for insiders on nothing; 🤷‍♂️👊Take it or leave it don’t care I know my bios 😃

0 · Reply

IPOtweet Apr. 16 at 12:40 PM

CG Oncology has delivered strong gains since its IPO—driven by positive trial data, a faster development timeline, and growing institutional backing. Momentum often follows data in the biotech sector. When the story strengthens, capital follows. Track IPO performance and emerging winners with IPO Pro: ipopro.renaissancecapital.com $CGON $IPO $IPOS #IPO #Biotech

0 · Reply

Grinding10 Apr. 15 at 5:57 AM

$CGON 1st half ⏱️ expedited results; time to shine; nitro zone; be there or not 🤷‍♂️; there’s zero board here so congrats to myself; This will be $95 or bought out by July 😎🫵; 3 years in decent average $34; do ursekf a favor I’m a bio man this is NITRO ZONE; check ISEE or SWAV last couple years for what I mean; blew one hot one; don’t follow me; make 💵💵on my patience; reminds me of 1 drug Regeneron and look at that chart👍Times ticking; don’t want follower’s etc just get in😎🤙

0 · Reply

Market Cap	5.90B
Revenue (ttm)	4.04M
Net Income (ttm)	-161.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,985.15%
Debt to Equity Ratio	0.00

Volume	507,000
Avg Vol	1,282,022
Day's Range	N/A - N/A
Shares Out	84.44M
Stochastic %K	54%
Beta	0.70
Analysts	Strong Sell
Price Target	$87.43